430 related articles for article (PubMed ID: 22856384)
1. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
[TBL] [Abstract][Full Text] [Related]
2. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
[TBL] [Abstract][Full Text] [Related]
3. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
4. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
5. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities in ADHD children treated with methylphenidate: a database study.
Kraut AA; Langner I; Lindemann C; Banaschewski T; Petermann U; Petermann F; Mikolajczyk RT; Garbe E
BMC Psychiatry; 2013 Jan; 13():11. PubMed ID: 23294623
[TBL] [Abstract][Full Text] [Related]
7. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
9. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
Song I; Lee MS; Lee EK; Shin JY
Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
[TBL] [Abstract][Full Text] [Related]
11. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
12. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
Hodgkins P; Sasané R; Meijer WM
Clin Ther; 2011 Feb; 33(2):188-203. PubMed ID: 21497704
[TBL] [Abstract][Full Text] [Related]
14. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Jaworowski S; Benarroch F; Gross-Tsur V
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of medically treated children with ADHD and type 1 diabetes in Germany - Analysis of two representative databases.
Kapellen TM; Reimann R; Kiess W; Kostev K
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1293-1297. PubMed ID: 27754966
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
[TBL] [Abstract][Full Text] [Related]
17. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
[TBL] [Abstract][Full Text] [Related]
18. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
[TBL] [Abstract][Full Text] [Related]
19. Prescriptions for ADHD medication, 2004-08.
Lillemoen PK; Kjosavik SR; Hunskår S; Ruths S
Tidsskr Nor Laegeforen; 2012 Sep; 132(16):1856-60. PubMed ID: 22986969
[TBL] [Abstract][Full Text] [Related]
20. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
